At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 96 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
This registry study collects information about people who have lymphoma (a cancer of the immune system) and human immunodeficiency virus (HIV) at the same time. A registry study gathers health records over time to learn more about these conditions. The sponsor is Rotkreuzklinikum München gGmbH.
Who can take part
- Lymphoma confirmed by tissue or cell tests (non-Hodgkin or Hodgkin lymphoma)
- HIV infection at the time the lymphoma was found
- Lymphoma diagnosed since 1 January 2010
- Adults aged 18 or over
- Written informed consent given
Who may not be able to
- HIV diagnosed more than 3 months after the lymphoma diagnosis
- Not able or willing to attend follow-up (for the forward-looking part of the study)
What taking part involves
- • Not stated — ask the trial team. This is a registry study, so it may only involve collecting your existing health information.
Time commitment: Not stated — ask the trial team about visits, duration, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 300
- Started
- 2021-08-25
- Last checked
- 2023-04
Plain English Summary
What is this study?
- • Testing a new treatment for aids related lymphoma
- • Clinical study - 300 participants
- • Retrospective und prospective registry on HIV-associated lymphoma
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with aids related lymphoma
Where?
- • Cardiff - University Hospital of Wales
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.
More detail
To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
- ✓HIV-infection at time of lymphoma diagnosis
- ✓Lymphoma diagnosis since 01.01.2010
- ✓Adult patients ≥ 18 years
- ✓Written agreement to take part
Who cannot take part
- ✗HIV-diagnosis \> 3 months after the diagnosis of malignant lymphoma
- ✗Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)
See the full criteria
Where Is This Study? (1 UK site)
University Hospital of Wales
Cardiff, United Kingdom
How to Get in Touch
Marcus Hentrich, MD
Sponsor contactCONTACT
Kai Hübel, MD
Sponsor contactCONTACT